Difficult bile duct cannulation: Do all roads lead to Rome?

Código QR

Difficult bile duct cannulation: Do all roads lead to Rome?

Guardado en:

Detalles Bibliográficos
Autor principal:	Marianna Arvanitakis
Formato:	article
Lenguaje:	EN
Publicado:	Georg Thieme Verlag KG 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/2554909a57f04099ae50c3785dca1ebf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Initial experience with a homemade “hybrid-tome” for needle-knife precut in patients with difficult biliary cannulation
por: Emilio J. De la Morena Madrigal, et al.
Publicado: (2021)

Transpancreatic precut papillotomy versus double-guidewire technique in difficult biliary cannulation: a systematic review and meta-analysis
por: Edson Guzmán-Calderón, et al.
Publicado: (2021)

Common bile duct size in malignant distal obstruction and lumen-apposing metal stents: a multicenter prospective study
por: Mihai Rimbaş, et al.
Publicado: (2021)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
por: Cartwright EJ, et al.
Publicado: (2013)

Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis
por: Gina M. Gallucci, et al.
Publicado: (2021)

Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition
por: Junichi Iwamoto, et al.
Publicado: (2021)

Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans
por: Neil Heraghty, et al.
Publicado: (2021)

Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”
por: Nikolaj W. Ørntoft, et al.
Publicado: (2021)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan SV, et al.
Publicado: (2015)

Is it time we split bowel preparation for all colonoscopies? Outcomes from a national survey of bowel preparation practice in the UK
por: Thomas Archer, et al.
Publicado: (2021)

Do gastroenterologists have medical inertia towards coeliac disease? A UK multicentre secondary care study
por: Hugo A Penny, et al.
Publicado: (2021)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Mohammad Shehab, et al.
Publicado: (2021)

Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Bishnu Sapkota, et al.
Publicado: (2021)

Integrated real-time imaging system, ‘IRIS’, Kangaroo feeding tube: a guide to placement and image interpretation
por: Stephen Taylor, et al.
Publicado: (2021)

Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study
por: Peter M Irving, et al.
Publicado: (2021)

Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina
por: Espul C, et al.
Publicado: (2012)

Stopping anti-TNF in CD remitters: pros and cons
por: Edouard Louis
Publicado: (2021)

DEDICATED PSYCHIATRY CLINIC FOR INFLAMMATORY BOWEL DISEASE PATIENTS HAS A POSITIVE IMPACT ON DEPRESSION SCORES
por: Kaleb Bogale, et al.
Publicado: (2021)

Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis
por: Yoshimitsu K
Publicado: (2014)

Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011)

New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
por: Chua DL, et al.
Publicado: (2014)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

Implementing Collaborative Care Management of Behavioral Health for Patients with Inflammatory Bowel Disease
por: Christine Beran, et al.
Publicado: (2021)

Impact of Diagnostic Delay on Disease Course in Pediatric Versus Adult-onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort
por: Alain M. Schoepfer, et al.
Publicado: (2021)

Update on entecavir in the management of severe forms of Hepatitis B
por: Sacco R
Publicado: (2012)

The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis
por: Jinming Wang, et al.
Publicado: (2021)

CCR 3: Annual Meeting of the Clinical Research Development Unit of Shahid Rajaei Educational and Medical Center
por: Hossein Karim, et al.
Publicado: (2020)

Incidence of ‘new-onset’ constipation and associated factors during lockdown due to the COVID-19 pandemic
por: Bryan Adrian Priego-Parra, et al.
Publicado: (2021)

Organoid vs In Vivo Mouse Model: Which is Better Research Tool to Understand the Biologic Mechanisms of Intestinal Epithelium?
por: Shinya Sugimoto, MD, PhD, et al.
Publicado: (2022)

Rebuttal to: Organoid vs Mouse Model: Which is a Better Research Tool to Understand the Biologic Mechanisms of Intestinal Epithelium?
por: Jordi Guiu, PhD, et al.
Publicado: (2022)

CMGH: The year in review
por: Klaus H. Kaestner, PhD, MS, et al.
Publicado: (2021)

Contents
Publicado: (2021)

Form Follows Function for Local Immune Responses in Pancreatic Cancer
por: Anna L. Means, PhD
Publicado: (2021)

Myeloid Cell Mediated Immune Suppression in Pancreatic CancerSummary
por: Samantha B. Kemp, et al.
Publicado: (2021)

Cover 2 - Tertiary Lymphoid Structures: Hub for Pancreatic Cancer Immune Response
Publicado: (2021)

An Epigenetic Switch Between Differentiation and Proliferation in Hepatoblastoma
por: Jeffrey H. Albrecht, MD
Publicado: (2021)

Editorial Board
Publicado: (2021)

Rebuttal to: In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
por: Shinya Sugimoto, MD, PhD, et al.
Publicado: (2022)

In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
por: Jordi Guiu, PhD, et al.
Publicado: (2022)